Condition: Long Term Follow-up · Sponsor: Arbutus Biopharma Corporation
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).
This description comes directly from the study's public registry record.
Michael Child · 267-332-6213 · mchild@arbutusbio.com
Always discuss trial participation with your own doctor first.
| Research and Education Inc. | San Diego, California, United States | Recruiting |
| University of Miami Miller School of Medicine | Miami, Florida, United States | Not Yet Recruiting |
| Infectious Disease Care | Hillsborough, New Jersey, United States | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Fiona Stanley Hospital | Murdoch, Australia | Not Yet Recruiting |
| Prince of Wales Hospital | Shatin, New Territories, Hong Kong | Recruiting |
| Queen Mary Hospital | Hong Kong, Hong Kong | Recruiting |
| Arensia Exploratory Medicine Moldova | Chisinau, Moldova | Recruiting |
| Asan Medial Center | Seoul, South Korea | Not Yet Recruiting |
| Changhua Christian Hospital | Changhua, Taiwan | Recruiting |
| Chia-Yi Christian Hospital | Chiayi City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06277037